Beta-Glucans for Cholesterol Management

Research suggests that beta-glucans derived from strains of the yeast-like fungus Aureobasidium pullulans may have some influence on cholesterol and lipid-related markers, though the current evidence is quite limited. The available studies consist of one small exploratory human trial involving only 16 healthy men and one animal study in obese diabetic mice, both from 2021, and neither can be considered definitive. The human study reported that a combination of two beta-glucan strains was associated with reductions in total and LDL cholesterol, while the animal study found more modest effects on fat-related blood markers with no significant changes in cholesterol. Given the very small sample sizes, preliminary nature of the findings, and the absence of large randomized controlled trials or meta-analyses in this specific area, the current evidence base is insufficient to draw firm conclusions, and larger, more rigorous studies are needed before meaningful assessments can be made.